HCA VS BDX Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend

Performance

HCA
10/100

HCA returned 4.32% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

BDX
100/100

BDX returned 4.47% in the last 12 months. Based on SPY's performance of -13.74%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

HCA
75/100

22 analysts offer 12-month price targets for HCA. Together, they have an average target of 265.95, the most optimistic target put HCA at 315 within 12-months and the most pessimistic has HCA at 200.

BDX
78/100

15 analysts offer 12-month price targets for BDX. Together, they have an average target of 276, the most optimistic target put BDX at 295 within 12-months and the most pessimistic has BDX at 250.

Technicals

HCA
50/100

HCA receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

BDX
14/100

BDX receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

HCA
10/100

HCA has missed earnings 6 times in the last 20 quarters.

BDX
100/100

BDX has missed earnings 0 times in the last 20 quarters.

Profit

HCA
78/100

Out of the last 20 quarters, HCA has had 20 profitable quarters and has increased their profits year over year on 10 of them.

BDX
80/100

Out of the last 20 quarters, BDX has had 20 profitable quarters and has increased their profits year over year on 9 of them.

Volatility

HCA
49/100

HCA has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

BDX
48/100

BDX has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

Dividend

HCA
23/100

HCA's most recent dividend was $0.35 per share, based on a share price of $237.58. It was a payout ratio of 11.37% compared to their total earnings.

BDX
10/100

BDX's most recent dividend was $0.87 per share, based on a share price of $233.76. It was a payout ratio of -139.53% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

HCA Healthcare, Inc. Summary

New York Stock Exchange / HCA
Healthcare
Medical - Care Facilities
HCA Healthcare, Inc., through its subsidiaries, provides health care services company in the United States. The company operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. It also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, the company operates psychiatric hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. As of December 31, 2021, it operated 182 hospitals, including 175 general and acute care hospitals, five psychiatric hospitals, and two rehabilitation hospitals; 125 freestanding surgery centers; and 21 freestanding endoscopy centers in 20 states and England. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.

Becton, Dickinson and Co. Summary

New York Stock Exchange / BDX
Healthcare
Medical - Instruments & Supplies
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.